[go: up one dir, main page]

ES2556585T3 - Composiciones que comprenden sulfato de salbutamol - Google Patents

Composiciones que comprenden sulfato de salbutamol Download PDF

Info

Publication number
ES2556585T3
ES2556585T3 ES12787053.3T ES12787053T ES2556585T3 ES 2556585 T3 ES2556585 T3 ES 2556585T3 ES 12787053 T ES12787053 T ES 12787053T ES 2556585 T3 ES2556585 T3 ES 2556585T3
Authority
ES
Spain
Prior art keywords
compositions
salbutamol sulfate
consisting essentially
component consisting
salbutamol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12787053.3T
Other languages
English (en)
Inventor
Stuart Corr
Timothy James Noakes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Application granted granted Critical
Publication of ES2556585T3 publication Critical patent/ES2556585T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica libre de tensioactivo que consiste esencialmente en: (a) un componente de fármaco que consiste en sulfato de salbutamol; y (b) un componente propulsor que consiste esencialmente en 1,1-difluoroetano (R-152a).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES12787053.3T 2011-10-12 2012-10-12 Composiciones que comprenden sulfato de salbutamol Active ES2556585T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201117621 2011-10-12
GB201117621A GB201117621D0 (en) 2011-10-12 2011-10-12 Compositions
PCT/GB2012/052542 WO2013054135A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (1)

Publication Number Publication Date
ES2556585T3 true ES2556585T3 (es) 2016-01-19

Family

ID=45091933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12787053.3T Active ES2556585T3 (es) 2011-10-12 2012-10-12 Composiciones que comprenden sulfato de salbutamol

Country Status (12)

Country Link
US (1) US9114164B2 (es)
EP (1) EP2766005B1 (es)
JP (1) JP5818290B2 (es)
CN (1) CN103857388B (es)
AU (1) AU2012322453B2 (es)
BR (1) BR112014008609B1 (es)
CA (1) CA2851764C (es)
ES (1) ES2556585T3 (es)
GB (1) GB201117621D0 (es)
MX (1) MX336225B (es)
WO (1) WO2013054135A1 (es)
ZA (1) ZA201402234B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3236967B1 (en) 2014-12-22 2019-10-16 SUDA Pharmaceuticals Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
EP3607936B1 (en) * 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
CA3037107C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CN113288869A (zh) * 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
FR3130554B1 (fr) 2021-12-20 2024-10-18 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE69232034T2 (de) * 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosolzusammensetzungen für Arzneimittelsuspensionen
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
AP960A (en) 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
AU750567B2 (en) * 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
GB2392915B (en) 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Also Published As

Publication number Publication date
MX2014004364A (es) 2014-05-27
BR112014008609A2 (pt) 2017-04-18
AU2012322453A1 (en) 2014-04-17
JP5818290B2 (ja) 2015-11-18
AU2012322453B2 (en) 2015-06-18
JP2014530231A (ja) 2014-11-17
CA2851764A1 (en) 2013-04-18
ZA201402234B (en) 2015-03-25
CN103857388A (zh) 2014-06-11
US20140286877A1 (en) 2014-09-25
BR112014008609B1 (pt) 2022-04-12
CA2851764C (en) 2017-02-14
US9114164B2 (en) 2015-08-25
CN103857388B (zh) 2016-09-28
GB201117621D0 (en) 2011-11-23
WO2013054135A1 (en) 2013-04-18
EP2766005B1 (en) 2015-11-25
EP2766005A1 (en) 2014-08-20
MX336225B (es) 2016-01-12

Similar Documents

Publication Publication Date Title
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CR20130556A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
BR112014012524A2 (pt) composições compreendendo um componente de estabilidade do prazo de validade
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CR20110110A (es) Composicion farmaceutica
MX2013000642A (es) Composiciones farmaceuticas.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
EA201170512A1 (ru) Композиция для перорального введения
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
ES2508165T3 (es) Lactoferrina y sustancia blanca
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas